Anti-resorptive therapies are widely prescribed across primary and secondary care in the management of osteoporosis. Shared decision making and clear communication is central to making the right choice of agent. Individualised management should take account of patient factors including dental health, GI disease, renal function, and other cautions and contraindications. Impact on the wider health economy is an additional consideration. Finally we will discuss the impact of the current COVID-19 pandemic on this area.
  • 1603282381-6f3caf109d14852a
    Dr Zakki Hassan-Smith
    Consultant Endocrinologist, University Hospitals Birmingham NHS Foundation Trust & Honorary Senior Research Fellow, University of Birmingham

    Zaki Hassan-Smith is a consultant endocrinologist at University Hospitals Birmingham NHS Foundation Trust with a sub-speciality interest in metabolic bone disease. He leads the bone genetics service and the clinical research programme. He is Clinical Senior Lecturer at Aston University Medical School. He is an honorary senior research fellow at the University of Birmingham. Previous posts include an honorary professorship in health and life sciences at Coventry University; clinical lectureship at the European Research Council and NIHR funded clinical research fellowships in Birmingham. He completed his PhD on the impact of steroid metabolism on sarcopenia. He trained in London and Birmingham.